Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial

Journal:

The Lancet Oncology

Published:

2025-09-12

DOI:

10.1016/s1470-2045(25)00363-8

Affiliations:

36

Authors:

47

Go to article

Institutions	Authors	Share
Erasmus MC Cancer Institute, Netherlands	8.000000	0.17
Amsterdam UMC, Netherlands	4.000000	0.09
Cancer Center Amsterdam (CCA), Netherlands	4.000000	0.09
Isala Clinics, Netherlands	3.000000	0.07
Leiden University Medical Center (LUMC), Netherlands	3.000000	0.07
Maasstad Hospital, Netherlands	3.000000	0.07
Medisch Spectrum Twente, Netherlands	2.000000	0.04
Radboud University Medical Centre (Radboudumc), RU, Netherlands	2.000000	0.04
Erasmus University Medical Center (Erasmus MC), Netherlands	2.000000	0.04
Amphia Hospital, Netherlands	2.000000	0.04
Maastricht University Medical Center+ (Maastricht UMC+), Netherlands	2.000000	0.04
Noordwest Hospital Group, Netherlands	2.000000	0.04
Catharina Hospital, Netherlands	2.000000	0.04
Jeroen Bosch Ziekenhuis (JBZ), Netherlands	1.000000	0.02
Frisius MC, Netherlands	1.000000	0.02
University Medical Center Utrecht (UMC Utrecht), Netherlands	1.000000	0.02
Onze Lieve Vrouwen Gasthuis (OLVG), Netherlands	1.000000	0.02
Elisabeth-Tweesteden Hospital (ETZ), Netherlands	1.000000	0.02
Reinier de Graaf Hospital, Netherlands	1.000000	0.02
St. Antonius Hospital, Netherlands	0.500000	0.01
Meander Medical Centre, Netherlands	0.500000	0.01

Interested in Oncology and Carcinogenesis?